Q0139 – Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (for esrd on dialysis)
HCPCS Level II code · Q codes: Temporary Codes
HCPCS codeQ0139
- Long description
- Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (for esrd on dialysis)
- Short description
- Ferumoxytol, esrd use
- Pricing indicator
51Drugs- Medicare coverage
CCarrier judgment – coverage decided by the Medicare contractor- BETOS category
O1EOther drugs- ASC
- Approved for ambulatory surgical centers
- Added
- January 1, 2010
- Last change
- January 1, 2017 – No change
Frequently asked questions
What is HCPCS code Q0139?
Q0139 is a HCPCS Level II code for injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (for esrd on dialysis).
Does Medicare cover Q0139?
The HCPCS file lists coverage code C: Carrier judgment – coverage decided by the Medicare contractor. Coverage and payment also depend on local coverage determinations and the patient’s plan.
Nearby Q codes
- Q0091 – Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory
- Q0092 – Set-up portable x-ray equipment
- Q0111 – Wet mounts, including preparations of vaginal, cervical or skin specimens
- Q0112 – All potassium hydroxide (koh) preparations
- Q0113 – Pinworm examinations
- Q0114 – Fern test
- Q0115 – Post-coital direct, qualitative examinations of vaginal or cervical mucous
- Q0138 – Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)
- Q0144 – Azithromycin dihydrate, oral, capsules/powder, 1 gram
- Q0155 – Dronabinol (syndros), 0.1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
- Q0161 – Chlorpromazine hydrochloride, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
- Q0162 – Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
- Q0163 – Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen
- Q0164 – Prochlorperazine maleate, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
- Q0166 – Granisetron hydrochloride, 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 24 hour dosage regimen
- Q0167 – Dronabinol, 2.5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
Source: CMS HCPCS Level II quarterly file, October 2026. Reference only – check payer policy before billing.